Sibnayal

Country: European Union

Language: Bulgarian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

Potassium citrate monohydrated, Potassium hydrogen carbonate

Available from:

Advicenne S.A.

ATC code:

A12BA30

INN (International Name):

potassium citrate, potassium hydrogen carbonate

Therapeutic group:

Mineral supplements

Therapeutic area:

Acidosis, Renal Tubular

Therapeutic indications:

Sibnayal is indicated for the treatment of distal renal tubular acidosis (dRTA) in adults, adolescents and children aged one year and older.

Product summary:

Revision: 2

Authorization status:

упълномощен

Authorization date:

2021-04-30

Patient Information leaflet

                                30
Б. ЛИСТОВКА
31
ЛИСТОВКА: ИНФОРМАЦИЯ ЗА ПОТРЕБИТЕЛЯ
SIBNAYAL 8 MEQ ГРАНУЛИ С УДЪЛЖЕНО
ОСВОБОЖДАВАНЕ
SIBNAYAL 24 MEQ ГРАНУЛИ С УДЪЛЖЕНО
ОСВОБОЖДАВАНЕ
калиев цитрат/калиев
хидрогенкарбонат
ПРОЧЕТЕТЕ ВНИМАТЕЛНО ЦЯЛАТА ЛИСТОВКА,
ПРЕДИ ДА ЗАПОЧНЕТЕ ДА ПРИЕМАТЕ ТОВА
ЛЕКАРСТВО,
ТЪЙ КАТО ТЯ СЪДЪРЖА ВАЖНА ЗА ВАС
ИНФОРМАЦИЯ.
-
Запазете тази листовка. Може да се
наложи да я прочетете отново.
-
Ако имате някакви допълнителни
въпроси, попитайте Вашия лекар или
фармацевт.
-
Това лекарство е предписано лично на
Вас. Не го преотстъпвайте на други
хора. То може
да им навреди, независимо че
признаците на тяхното заболяване са
същите като Вашите.
-
Ако получите някакви нежелани
реакции, уведомете Вашия лекар или
фармацевт. Това
включва всички възможни нежелани
реакции, неописани в тази листовка.
Вижте точка 4.
КАКВО СЪДЪРЖА ТАЗИ ЛИСТОВКА
1.
Какво представлява Sibnayal и за какво се
използва
2.
Какво трябва да знаете, преди да
приемете Sibnayal
3.
Как да приемате Sibnayal
4.
Възможни нежелани реакции
5.
Как да съхранявате Sibnayal
6.
Съдържание на опаковката и
допълнителна информация
1.
КАКВО ПРЕДСТАВЛЯВА SIBNAYAL И ЗА КАКВО СЕ
ИЗПОЛЗВА
Sibnayal съдържа две активни веще
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ПРИЛОЖЕНИЕ I
КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА
2
1.
ИМЕ НА ЛЕКАРСТВЕНИЯ ПРОДУКТ
Sibnayal 8 mEq гранули с удължено
освобождаване
Sibnayal 24 mEq гранули с удължено
освобождаване
2.
КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ
Sibnayal 8 mEq гранули с удължено
освобождаване
Едно саше съдържа 282 mg калиев цитрат и
527 mg калиев хидрогенкарбонат.
Това съответства на 7,9 mEq алкали (т.е. 2,6
mEq цитрат и 5,3 mEq хидрогенкарбонат) и на
7,9
mEq калий (т.е. 308 mg калий).
Sibnayal 24 mEq гранули с удължено
освобождаване
Едно саше съдържа 847 mg калиев цитрат и
1582 mg калиев хидрогенкарбонат.
Това съответства на 23,6 mEq алкали (т.е. 7,8
mEq цитрат и 15,8 mEq хидрогенкарбонат) и на
23,6 mEq калий (т.е. 924 mg калий).
За пълния списък на помощните
вещества вижте точка 6.1.
3.
ЛЕКАРСТВЕНА ФОРМА
Гранула с удължено освобождаване
Зелена (калиев цитрат) и бяла (калиев
хидрогенкарбонат), двойноизпъкнала,
диаметър 2 mm.
4.
КЛИНИЧНИ ДАННИ
4.1
ТЕРАПЕВТИЧНИ ПОКАЗАНИЯ
Sibnayal е показан за лечение на дистална
бъбречна тубулна ацидоза (distal renal tubular
acidosis,
dRTA) при възрастни, юноши и деца на
възраст една година и повече.
4.2
ДОЗИРОВКА И НАЧИН НА ПРИЛОЖЕНИЕ
Дозировка
Прилаганата доза е въз основа на
възрастта и телесното тегло.
Когато с
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Spanish 30-06-2023
Public Assessment Report Public Assessment Report Spanish 03-05-2021
Patient Information leaflet Patient Information leaflet Czech 30-06-2023
Public Assessment Report Public Assessment Report Czech 03-05-2021
Patient Information leaflet Patient Information leaflet Danish 30-06-2023
Public Assessment Report Public Assessment Report Danish 03-05-2021
Patient Information leaflet Patient Information leaflet German 30-06-2023
Public Assessment Report Public Assessment Report German 03-05-2021
Patient Information leaflet Patient Information leaflet Estonian 30-06-2023
Public Assessment Report Public Assessment Report Estonian 03-05-2021
Patient Information leaflet Patient Information leaflet Greek 30-06-2023
Public Assessment Report Public Assessment Report Greek 03-05-2021
Patient Information leaflet Patient Information leaflet English 30-06-2023
Public Assessment Report Public Assessment Report English 03-05-2021
Patient Information leaflet Patient Information leaflet French 30-06-2023
Public Assessment Report Public Assessment Report French 03-05-2021
Patient Information leaflet Patient Information leaflet Italian 30-06-2023
Public Assessment Report Public Assessment Report Italian 03-05-2021
Patient Information leaflet Patient Information leaflet Latvian 30-06-2023
Public Assessment Report Public Assessment Report Latvian 03-05-2021
Patient Information leaflet Patient Information leaflet Lithuanian 30-06-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 30-06-2023
Public Assessment Report Public Assessment Report Lithuanian 03-05-2021
Patient Information leaflet Patient Information leaflet Hungarian 30-06-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 30-06-2023
Public Assessment Report Public Assessment Report Hungarian 03-05-2021
Patient Information leaflet Patient Information leaflet Maltese 30-06-2023
Public Assessment Report Public Assessment Report Maltese 03-05-2021
Patient Information leaflet Patient Information leaflet Dutch 30-06-2023
Public Assessment Report Public Assessment Report Dutch 03-05-2021
Patient Information leaflet Patient Information leaflet Polish 30-06-2023
Public Assessment Report Public Assessment Report Polish 03-05-2021
Patient Information leaflet Patient Information leaflet Portuguese 30-06-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 30-06-2023
Public Assessment Report Public Assessment Report Portuguese 03-05-2021
Patient Information leaflet Patient Information leaflet Romanian 30-06-2023
Public Assessment Report Public Assessment Report Romanian 03-05-2021
Patient Information leaflet Patient Information leaflet Slovak 30-06-2023
Public Assessment Report Public Assessment Report Slovak 03-05-2021
Patient Information leaflet Patient Information leaflet Slovenian 30-06-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 30-06-2023
Public Assessment Report Public Assessment Report Slovenian 03-05-2021
Patient Information leaflet Patient Information leaflet Finnish 30-06-2023
Public Assessment Report Public Assessment Report Finnish 03-05-2021
Patient Information leaflet Patient Information leaflet Swedish 30-06-2023
Public Assessment Report Public Assessment Report Swedish 03-05-2021
Patient Information leaflet Patient Information leaflet Norwegian 30-06-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 30-06-2023
Patient Information leaflet Patient Information leaflet Icelandic 30-06-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 30-06-2023
Patient Information leaflet Patient Information leaflet Croatian 30-06-2023
Public Assessment Report Public Assessment Report Croatian 03-05-2021

View documents history